5-Year vs. 12-Year Exclusivity: The Complete Hatch-Waxman and BPCIA Playbook for Pharma IP Strategy
Two federal statutes govern most of what happens when a pharmaceutical patent expires in the United States. One dates to […]
Track Branded Generic Launches with Drug Patent Data: The Competitive Intelligence Playbook
Every year, billions of dollars in branded drug revenue evaporate on a single day: the day a generic or branded
Patent Thickets Exposed: How Drug Companies Lock Out Generics for Decades After Their Core Patent Expires
AbbVie held Humira’s U.S. market alone for twenty years. Not because it held one brilliant patent, but because it built
Branded Generic ROI: The Cold Math Behind a Controversial Strategy
Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a
Branded Generic ROI: The Cold Math Behind a Controversial Strategy Read Post »
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit
The difference between first place and second place in the generic drug market is not measured in prestige. It is
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit Read Post »
How Brand-Name Drug Companies Delay Generic Competition: Product Hopping, Patent Thickets, and Market Exclusivity Tactics Explained
AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan
Your 2-Year LOE Window Is a 5-Year Death March: The Real Pharmaceutical Patent Cliff Timeline
Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue
Patent Thickets Decoded: How to Find the Real Expiration Date for Blockbuster Drug Patents
The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More
Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More Read Post »
